AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”
2
Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race
3
Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion
4
After $400M cyber exit, ex-IntSights CEO raises $11M to build AI app for personalized sports highlights
5
Why Apple paid billions for a company with no revenue
More news

Teva

20 stories about Teva
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva’s 2026 forecast disappoints despite strong finish to 2025

28.01.26|Sophie Shulman
Lower revenue guidance overshadows rapid growth in branded drugs.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva bets on vitiligo drug in deal worth up to $500 million

12.01.26|Sophie Shulman
Agreement with Royalty Pharma underscores shift toward branded medicines.
המטה הגלובלי של חברת טבע בת"א

Teva’s branded drugs spark investor optimism

06.11.25|Sophie Shulman
The pharmaceutical company recorded its 11th consecutive quarter of growth, with revenue of $4.5 billion, thanks to sales of its brand-name drugs Austedo, Ajovy and Uzedy, which jumped 33%.
ריצ'רד פרנסיס מפגש העיתונאים

Teva shares soar on strong third-quarter performance

05.11.25|Sophie Shulman
Revenue climbs 3% to $4.5 billion, exceeding analysts’ expectations.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva returns to profit in Q2 but misses on revenue

30.07.25|Sophie Shulman
Austedo disappoints, while Uzedy and Ajovy drive upside in brand-name drugs.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s quiet layoff announcement reveals bold restructuring plan

08.05.25|Sophie Shulman
CEO signals this is ‘just the first step’ in multi-year effort to streamline and scale.
מנכ"ל טבע ריצ'רד פרנסיס מפגש עיתונאים 2025

Teva to cut 3,000 jobs by 2027 in drive toward higher profit margins

07.05.25|Sophie Shulman
Pharma giant targets 30% operating margin by laying off approximately 8% of its global workforce as it boosts forecasts on drug sales and updates its "Pivot to Growth" strategy. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva signals return to fundraising after decade-long crisis

08.02.25|Sophie Shulman
Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman
Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman
Duvakitug signals a brighter future for the Israeli pharma giant. 
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman
Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.
בורסה תל אביב מסחר

How dual-listed companies boost profits without earning more

08.12.24|Uri Tal Tenne
The creative accounting tricks Israeli firms use to inflate earnings.
Noam Solomon Immunai

Immunai and Teva launch multi-tear AI collaboration for smarter drug development

14.11.24|CTech
The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.  
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
קופקסון זריקה תרופה טבע

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman
Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
ריצ'רד פרנסיס נשיא ו מנכ"ל חברת טבע

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
הנהלת מאנדיי קום MONDAY COM

How Monday overtook NICE and why Teva is on course to becoming Israel's highest-valued company

24.07.24|Sophie Shulman
While Wall Street transitions from growth stocks to value stocks, the balance of power among Israeli giants is also shifting. This reflects the speed at which the market punishes companies and rewards those leading growth processes, returning to profitability, or correctly identifying emerging fields.
More Articles